A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 μg ethinyl estradiol combined with 100 μg levonorgestrel

Contraception

Volumn 71, Issue 2, 2005, Pages 111-117

  Skouby, Sven O ^a   Endrikat, Jan ^b   Düsterberg, Bernd ^b   Schmidt, Werner ^c   Gerlinger, Christoph ^b   Wessel, Jens ^b   Goldstein, Henri ^a   Jespersen, Joergen ^d  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b BAYER PHARMA AG   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

^d ESBJERG HOSPITAL   (Denmark)

Author keywords

Carbohydrate metabolism; Dose reduction; Ethinylestradiol; Hemostasis; Levonorgestrel; Lipids; Oral contraceptives

Indexed keywords

C PEPTIDE; CARBOHYDRATE; ETHINYLESTRADIOL; FATTY ACID; GLUCOSE; INSULIN; LEVONORGESTREL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL CONTRACEPTIVE AGENT; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACNE; ADULT; AREA UNDER THE CURVE; ARTICLE; CARBOHYDRATE METABOLISM; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; EVALUATION; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MASTALGIA; NAUSEA; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL; VOLUNTEER;

EID: 13544263383     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2004.08.017     Document Type: Article

References (22)

1. B. Düsterberg, H. Ellman, and U. Müller A three-year clinical investigation into efficacy, cycle control and tolerability of a new low-dose monophasic oral contraceptive containing gestodene Gynecol. Endocrinol. 10 1996 33 39
2. J. Nevinny-Stickel German trial of an oral contraceptive containing 0.150 mg desogestrel plus 0.020 mg ethinylestradiol Acta Obstet. Gynecol. Scand. 44 Suppl. 1988 19 21
3. J.R. Newton, C. d'Arcangues, and P.E. Hall A review of 'once a month' combined injectable contraceptives Obstet. Gynecol. 14 1994 1 34
4. N. Maitra, R. Kulier, K. Blomenkamp, F. Helmerhorst, and A. Gulmezoglu Progestogens in combined oral contraceptives for contraception Cochrane Database Syst. Rev. 3 2004 CD004861
5. R. Bannemerschult, J.P. Hanker, and C. Wünsch A multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control, and safety of a new low dose oral contraceptive containing 20 μg ethinyl estradiol and 100 μg levonorgestrel over six treatment cycles Contraception 56 1997 285 290
6. R.C. Hite, R. Bannemerschult, P. Fox-Kuchenbecker, R. Turck, and K. Brill Large observational trial of a new low-dose oral contraceptive containing 20 μg ethinylestradiol and 100 μg levonorgestrel (Miranova) in Germany Eur. J. Contracept. Reprod. Health Care 4 1999 7 13
7. J. Endrikat, B. Düsterberg, A. Ruebig, C. Gerlinger, and T. Strowitzki Comparison of efficacy, cycle control and tolerability of two low-dose oral contraceptives in a multicenter clinical study Contraception 60 1999 269 274
8. U.H. Winkler, A.E. Schindler, J. Endrikat, and B. Düsterberg A comparative study of the effects on the hemostatic system of two monophasic gestodene oral contraceptives containing 20 μg and 30 μg ethinylestradiol Contraception 53 1996 75 84
9. D. Crook, and I. Godsland Safety evaluation of modern oral contraceptives Contraception 57 1998 189 201
10. C. Kluft, M.P. De Maat, L.A. Heineman, M. Spannagl, and W. Schramm Importance of levonorgestrel dose in oral contraceptives for effects on coagulation Lancet 354 1999 832 833
11. J. Endrikat, C. Klipping, and M. Cronin An open label, comparative study of the effects of a dose reduce oral contraceptive containing 20 μg ethinylestradiol and 100 μg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables Contraception 65 2002 215 221
12. 2 precipitation technique in human serum Clin. Chim. Acta 158 1986 33 41
13. W.T. Friedewald, R.I. Levy, and D.S. Fredrickson Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the ultracentrifuge Clin. Chem. 18 1972 499 502
14. G.E. Robinson, and S. Registrar Low-dose combined oral contraceptives Br. J. Obstet. Gynaecol. 101 1994 1036 1041
15. NIH Consensus Conference. Triglyceride, high-density lipoprotein, and coronary disease. NIH Consensus Development Panel on Triglyceride High Density Lipoprotein, and Coronary Heart Disease JAMA 269 1993 505 510
16. S.B. Hulley, R.H. Rosenman, R.D. Bawol, and R.J. Brand Epidemiology as a guide to clinical decisions. The association between triglycerides and coronary heart disease N. Engl. J. Med. 302 1982 1383 1389
17. R.J. Jarret, and H.J. Graver Changes in oral glucose tolerance during the menstrual cycle Br. Med. J. 2 1968 528 529
18. L. Chasan Taber, W.C. Willett, and M.J. Stampfer A prospective study of oral contraceptives and NIDDM among US women Diabetes Care 20 1997 330 335
19. R.M. Watanabe, C.G. Azen, S. Roy, J.A. Perlamn, and R.N. Bergman Defects in carbohydrate metabolism in oral contraceptive users without apparent metabolic risk factors J. Clin. Endocrinol. Metab. 78 1994 1277 1283
20. R. Russel-Briefel, T.M. Ezzati, J.A. Perlman, and R.S. Murphy Impaired glucose tolerance in women using oral contraceptives: United States 1976-1980 Chron.-J. 40 1987 3 11
21. I.J. Gaspard, F. Demeyer, C.B. Jaminet, A.J. Scheen, and P.J. Lefebbvre Influence of two low-dose oral contraceptives containing ethinylestradiol (20 μg) and desogestrel or gestodene on carbohydrate metabolism during 1 year of use Gynecol. Endocrinol. 10 Suppl. 2 1996 179 181
22. I.F. Godsland, C. Walton, C. Felton, A. Proudler, A. Patel, and V. Wynn Insulin resistance, secretion and metabolism in users of oral contraceptives J. Clin. Endocrinol. Metab. 74 1992 64 70